<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918747</url>
  </required_header>
  <id_info>
    <org_study_id>HNCH-NKT-2016</org_study_id>
    <nct_id>NCT02918747</nct_id>
  </id_info>
  <brief_title>PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage</brief_title>
  <official_title>P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's
      lymphoma and shows extremely poor survival. Several retrospective studies and singe-arm
      prospective phase 2 studies have shown that pegaspargase combined Gemox or CHOP regimen
      achieved a promising efficacy in treatment of ENKTL. However, there is no prospective study
      to compare the efficacy of these two regimens. This prospective pilot study to compare the
      efficacy and safety of the P-Gemoxd chemotherapy regimen with those of the P-CHOP regimen for
      stage IE to IIE ENKTL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment PA-Gemoxd dosages were as follows: days 1 and 5, 30-min intravenous infusion of 800
      mg/m2 gemcitabine; day 1, 2-h intravenous infusion of 85 mg/m2 oxaliplatin; day 1, deep
      intramuscular injection of 2000 U/m2 PEG-ASP at two different sites; d1-5, intravenous
      infusion of 15mg dexamethasone. The regimen was repeated every 3 weeks for four cycles
      followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal
      radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6
      weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate（complete remission rate + partial remission rate）</measure>
    <time_frame>every 6 weeks,up to completion of treatment (approximately 6 months)</time_frame>
    <description>The criteria for the efficacy evaluation (overall response rate and complete remission) of the regimen is according to the following article: Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
    <description>time from the date of enrollment to date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
    <description>overall survival (OS): time from the date of enrollment to date of death from any cause, or date of lost follow-up, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events according to Common Terminology Criteria for Adverse Events v3.0</measure>
    <time_frame>every 3 weeks,up to completion of treatment (approximately 6 months)</time_frame>
    <description>including hematological safety and non-hematological safety. All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Epstein-Barr virus (EBV) DNA copies</measure>
    <time_frame>every 3 weeks,up to completion of treatment (approximately 6 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>P-Gemoxd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.
Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.
IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Pegaspargase 2000U/m2 im，day 1； cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.
IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-Gemoxd</arm_group_label>
    <arm_group_label>P-CHOP</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-Gemoxd</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four</description>
    <arm_group_label>P-Gemoxd</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-Gemoxd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.</description>
    <arm_group_label>P-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.</description>
    <arm_group_label>P-Gemoxd</arm_group_label>
    <arm_group_label>P-CHOP</arm_group_label>
    <other_name>intensity-modulated radiation treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pathologically confirmed, previously untreated ENKTL with stage I/II (for stage I, the
             patients should have one of the following risk factors: EBV-DNA &gt; upper limit of
             normal, lesions beyond nasal, fever, LDH elevation);

          2. age range from 18 to 70 years;

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          4. at least one measurable lesion;

          5. adequate haematologic function (haemoglobin &gt; 8.0 g/l, absolute neutrophil count &gt;
             1500/ml, platelets &gt; 75,000/l),

          6. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of
             normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper
             limit of normal),

          7. Hepatitis B virus carriers should have normal HBV-DNA copies and should use antiviral
             drugs. For patients with elevated HBV-DNA, should use antiviral drugs until the
             HBV-DNA decrease to &lt; the upper limit of normal.

          8. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50
             ml/min);

          9. normal coagulation function and electrocardiogram results.

         10. Prior chemotherapy and radiotherapy should have been completed &gt;4 weeks earlier,

         11. willingness to provide written informed consent.

        Exclusion Criteria:

          1. mismatch the inclusion criteria

          2. systematic central nervous system involvement, previous or concomitant malignancies
             and any coexisting medical problems that could cause poor compliance with the study
             protocol.

          3. primary lesion not from the upper respiratory
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingyong Yi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pingyong Yi, MD.</last_name>
    <phone>(86-0731)89762281</phone>
    <email>yipingy1964@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yajun Li, MD.</last_name>
    <phone>(86-0731)89762281</phone>
    <email>liyajun9@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>4100013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pingyong Yi, MD.</last_name>
      <phone>(86-0731)89762281</phone>
      <email>yipingy1964@163.com</email>
    </contact>
    <investigator>
      <last_name>Pingyong Yi, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

